Autres langues Amgen Inc. Buenos Aires S.E.

Actions

Cours en clôture Buenos Aires S.E. Autres places de cotation 00:00:00 24/06/2024			Varia. 5j.	Varia. 1 janv.
13 942 ^ARS	+4,20%		+10,93%	+49,37%

25/06	Badaboum
21/06	La FDA américaine approuve le médicament de Roche pour un trouble sanguin chronique	RE

Out with AI, in with defensive stocks	25/06
Valores destacados al cierre del mercado norteamericano	25/06
Borsa di Italia: Bang!	25/06
Bolsa de Madrid: ¡Bang!	25/06
US FDA approves Roche's drug for a chronic blood disorder	21/06
Amgen : Bringing Cardiovascular Care to the Heart of Communities	20/06
Amgen : Continues to Propel BiTE® Technology Innovation	20/06
Amgen Gets FDA Approval to Treat Aggressive Leukemia Type with Blincyto	14/06
Amgen : Continues to Propel BiTE® Technology Innovation	14/06
Amgen Says FDA Approves Blincyto to Treat Type of Blood Cancer	14/06
FDA APPROVES BLINCYTO® (BLINATUMOMAB) IN CD19-POSITIVE PHILADELPHIA CHROMOSOME-NEGATIVE B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA (B-ALL) IN THE CONSOLIDATION PHASE	14/06
Amgen Inc. Announces U.S. Food and Drug Administration Approves Blincyto	14/06
Sector Update: Health Care Stocks Softer Friday Afternoon	14/06
Race Oncology Validates Efficacy of Blood Cancer Therapy in Animal Study; Shares Rise 6%	13/06
AMGEN TO PRESENT INNOVATIVE RHEUMATOLOGY RESEARCH AT EULAR 2024	12/06
Amgen : Leaders Hail Southern California’s Emergence as Biotech Innovation Hub	11/06
Updates On Aflibercept Biosimilar Approvals And BPCIA Litigation	11/06
FDA Approves Amgen's BKEMV, The First Eculizumab Biosimilar	11/06
Amgen Files BPCIA Complaint Against Celltrion Regarding Denosumab	10/06
AbbVie's tight grip on Humira market raises concerns about biosimilars	07/06

Aucun résultat pour cette recherche